“Assessing how to help researchers and businesses with their IP should be driven by what they want to do with it.”

Through experience in both basic and pre-clinical research in Australia and the USA, Michael has gained technical expertise in immunology, antibody technologies, haematology and apoptosis.

Michael completed his doctoral studies and a postdoctoral fellowship at the Walter and Eliza Hall Institute of Medical Research where he focused on mechanisms that control the body’s immune system. In addition, Michael was involved in a collaborative industry-academia oncology effort to study anti-cancer BH3-mimetic compounds. His research led to a series of publications in high profile journals including Cell and Blood.

With an interest in biologics research and development, Michael joined the Therapeutics Program at the Massachusetts General Hospital in Boston, USA. Here Michael worked with a team of biochemists, chemists and computational biologists on the design and development of methods of eradicating cancer cells using combinatorial targeting approaches based on monoclonal antibodies and antibody-variants.

Michael understands the creative process that underpins break-through medical discoveries as well as the process of turning these discoveries into a practical and commercial success. “I am driven to help researchers extract value from their discoveries”. 

Qualifications

  • PhD – in Immunology/Haematology –  The University of Melbourne
  • Bachelor of Science (Hons) – The University of Melbourne
  • Bachelor of Science/Bachelor Business – Swinburne University of Technology